HIM
TEVA icon

Hillsdale Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hillsdale Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-914
Closed -$20.1K – 702
2024
Q4 		$20.1K Hold
914
– – ﹤0.01% 463
2024
Q3 		$16.5K Buy
914
+254
+38% +$4.45K ﹤0.01% 479
2024
Q2 		$10.7K Buy
+660
New +$10.2K ﹤0.01% 479
2016
Q1 		– Sell
-6,080
Closed -$399K – 547
2015
Q4 		$399K Sell
6,080
-1,200
-16% -$74.2K 0.15% 138
2015
Q3 		$411K Buy
7,280
+1,380
+23% +$89.5K 0.14% 139
2015
Q2 		$349K Sell
5,900
-100
-2% -$6.17K 0.11% 185
2015
Q1 		$374K Buy
6,000
+2,000
+50% +$116K 0.1% 189
2014
Q4 		$230K Sell
4,000
-1,000
-20% -$55.7K 0.06% 304
2014
Q3 		$269K Buy
+5,000
New +$265K 0.09% 225

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Hillsdale Investment Management's TEVA Position: Q1 2025 in Review

Hillsdale Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 914 shares — an estimated $20.1K sold.

Hillsdale Investment Management first reported a position in TEVA in Q3 2014 and held it in 9 quarters. The position peaked at $411K in Q3 2015. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Hillsdale Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 914 Teva Pharmaceuticals shares in Q1 2025, an estimated $20.1K.
  • Hillsdale Investment Management first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 9 quarters.
  • Hillsdale Investment Management's Teva Pharmaceuticals position peaked at $411K in Q3 2015.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Hillsdale Investment Management's 13F filing for Q1 2025, filed 9 May 2025.